SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA).
Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending Clinical Programs
June 19, 2017
SOUTHBOROUGH, MA – May 30, 2017 – Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval of ZEJULA™.
Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive Year
May 15, 2017
Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts
Veristat Opens New Office in North Carolina Today
February 1, 2017
Veristat announced today the official opening of its new office in Morrisville, NC.
Read More
Veristat Appoints James Roach, MD as Chief Medical Officer
November 7, 2016
Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings
SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
Veristat Formalizes its Strategic Decision Consulting Services
November 1, 2016
SOUTHBOROUGH, MA – November 01, 2016 – Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.
Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals
September 20, 2016
Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat Acknowledged for its Rapid Growth on the Inc. 5000 List of America’s Fastest-Growing Private Companies
August 17, 2016
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
SOUTHBOROUGH, MA – August 17, 2016 – Veristat announced today that it has been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
Two of Veristat’s statistical and adaptive design experts submitted a research paper which was published in the June 2016 issue of the Journal of Bioanalysis & Biostatistics.
Accelerates Hiring & Plans to Open Office in Raleigh-Durham, North Carolina